Corcept Therapeutics | CORT - Current Liabilities


Corcept Therapeutics reported $172.26M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Alaunos Therapeutics USD 921K 153K Sep/2025
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
Ardelyx USD 83.39M 1.67M Sep/2025
Aurora Cannabis CAD 124.12M 32.76M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Canopy Growth CAD 81.1M 17.56M Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Knight Therapeutics CAD 118.15M 12.32M Sep/2024
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 32B 286M Sep/2025
Novartis USD 32B 286M Sep/2025
Pacira USD 107.08M 206.09M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Supernus Pharmaceuticals USD 330.63M 44.27M Sep/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025